Skip to main content
. 2022 Mar 16;27(5):e406–e409. doi: 10.1093/oncolo/oyac037

Table 1.

Common genomic alterations present at baseline (pre-ICI) and during or completion of ICI therapy (post-ICI).

Gene Pre-ICI, n (%) Post-ICI, n (%)
TP53 21 (54) 21 (54)
TERT 19 (49) 23 (59)
BRCA1/BRCA2 13 (33) 13 (33)
CCND1/CCND2/CDKN2A/CDK6 6 (15) 4 (10)
RAS 5 (13) 4 (10)
PIK3CA 5 (13) 5 (13)
EGFR 3 (8) 4 (10)
FGFR2/3 3 (8) 5 (13)
ERBB2 1 (3) 1 (3)
Rb 1 (3) 3 (8)
ALK 1 (3) 2 (5)

Abbreviation: ICI, immune checkpoint inhibitor.